CannabCo Pharmaceutical Corp. (CannabCo), a Canadian company located in 
Brampton, Ontario, is pleased to announce its intent to expand on production 
and product offerings resulting from the overwhelming interest received on 
deployment of the PURECANN(TM) technology. Less than a month ago, CannabCo 
announced PURECANN, the technology responsible for the production of Odourless 
Cannabis(TM), a global cannabis first, and since that time, PURECANN has 
seemingly created a new market segment in the industry. 

Originally developed for the medical market and dubbed "PURECANN", the 
technology was designed to eliminate much of the harshness of smoking cannabis 
by consumers without losing any of its properties. "Since the time of the 
announcement, the response has been overwhelming", said President & CEO Mark 
Pellicane, "Within hours of the announcement we were inundated with public 
inquiries."

Numerous products exist to control cannabis odour both during the production 
process and aftermarket. "No one thought to eliminate the odour at the source, 
the product itself," said Pellicane, "we did this with the deployment of 
PURECANN."

CannabCo has since been featured in multiple live interviews, and press 
coverage ranging from cannabis specific publications to seemingly unrelated 
market segments such as publications for the cottage industry. "Everyone wants 
to know the impact of this technology on different market segments both social, 
and business related," said Pellicane, "in virtually all cases, the underlying 
theme was the positive aspect of the elimination of the cannabis smell 
associated with people using the product." Pellicane further goes on to state 
that the company has created an entirely new market segment addressing what 
some consider a fundamental issue surrounding cannabis users, the odour.

"There is no question that there exists a huge demand for odourless products 
beyond the standard combustion of dry bud," said Mark Novak, COO of CannabCo, 
"We are currently exploring numerous products both consumable, and 
non-consumable which will be produced from the manufacturing facility using 
PURECANN as the base technology."

CannabCo is currently raising capital through an in-house non-brokered private 
placement. The company is constructing its pilot facility in Brampton, Ontario, 
and has received a Confirmation of Readiness notification from Health Canada 
for their pending cannabis license. 

CannabCo further intends to pursue a Canadian public listing targeting Q1-Q2 of 
2020 and management has retained legal securities council to this effect. The 
company is currently using MNP for audit purposes.

About PURECANN

PURECANN is a technology under the exclusive right to use by CannabCo for the 
production of Odourless Cannabis(TM). The process is EU GMP compliant and is 
designed to produce cannabis product with the following characteristics:

    - Virtually undetectable odour of dry product during storage 
    - Greatly reduced cannabis odor (virtually undetectable) during 
      combustion 
    - Reduces harshness resulting in a very smooth smoke on combustion 
    - May be used to produce a "connoisseur" product for a unique market 
      segment 
    - Less residual heavy feeling "day after effect" associated with smoking
      cannabis

Upon receiving its license from Health Canada, CannabCo will have exclusive 
rights to deploy the technology for use in its Canadian production.

About CannabCo Pharmaceutical Corp.

CannabCo Pharmaceutical Corp. is a Canadian based full service cannabis company 
with operations in Brampton, Ontario. The company has received its 
"Confirmation of Readiness" from Health Canada to become a licensed producer 
and is currently building out its pilot facility in the Brampton Area. The 
company intends to use an enhanced technology known as PHOENIX for its 
cultivation initiatives claiming a high productivity and significantly lower 
cost per gram than traditional grows. The company intends to launch extraction 
initiatives as well as enter the oils, extracts, and consumable markets upon 
completion of its Brampton Facility. The facility is pursuing EU GMP status 
allowing access to the underserviced global pharmaceutical market. 

Forward Looking Statements
This press release may contain certain "forward-looking information" and 
"forward-looking statements" within the meaning of applicable securities 
legislation. All information contained herein that is not historical in nature 
may constitute forward-looking information. Forward-looking statements may be 
identified by statements containing the words "believes", "anticipates", 
"plans", "intends", "will", "should", "expects", "continue", "estimate", 
"forecasts" and other similar expressions. Actual results and developments may 
differ materially from those contemplated by these statements. Although 
CannabCo believes that the expectations reflected in forward-looking statements 
in this press release are reasonable, there can be no assurance that such 
statements will prove to be accurate. Future events and results could differ 
materially from those set forth in, contemplated by, or underlying the 
forward-looking statements in this press release. Comments and claims related 
to PHOENIX and PURECANN are based solely on that observed and the opinions of 
management as well as third party verifications provided to CannabCo from 
industry experts.

For further information: Phillip Chen, Chief of Business Development, CannabCo 
Pharmaceutical Corp., +1 (905) 771-8576 x 231; info@cannabco.ca, www.cannabco.ca

SOURCE: CannabCo Pharmaceutical Corp.